The genomes of classical swine fever virus (CSFV) vaccine strains are poorly characterized, and the mechanisms for their attenuation remain unknown. The aim of the present study was to characterize the 3' noncoding region (3' NCR) of a number of attenuated vaccine strains of CSFV in order to examine changes in the viral genome after attenuation. The results showed that the 3' NCR:s of Porcivac, Rovac, Russian LK and original Chinese vaccine strain contain insertions very similar to that present in the published nucleotide sequence of the C-strain. Phylogenetic analysis showed that the vaccine strains Porcivac, Rovac and Russian LK vaccine were closely related to each other, but that these three strains showed a distant relationship with two tested variants of the Chinese vaccine strain (C-strain and original Chinese vaccine). The 3' NCR insertion is not likely to be a marker for attenuation of the virus, since many CSFV vaccine strains do not contain the insertion. The fact that the insertions occur in lapinized vaccine strains suggests that these genetic segments were incorporated during the adaptation of the virus to the rabbit host system.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1008095109033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MPXV: Update on Morphological and Morphogenesis Aspects Through Transmission and Scanning Electron Microscopies and 3D Reconstruction.
J Med Virol
January 2025
Laboratório de Morfologia e Morfogênese Viral, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz-Fiocruz, Rio de Janeiro, Brazil.
An unprecedented global outbreak caused by the monkeypox virus (MPXV) prompted the World Health Organization to declare a public health emergency of international concern on July 23, 2022. Therapeutics and vaccines for MPXV are not widely available, necessitating further studies, particularly in drug repurposing area. To this end, the standardization of in vitro infection systems is essential.
View Article and Find Full Text PDFConstruction of a Vero cell line expression human KREMEN1 for the development of CVA6 vaccines.
Virol J
January 2025
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, PR China.
Coxsackievirus A6 (CVA6) has emerged as a major pathogen causing hand, foot and mouth disease (HFMD) outbreaks worldwide. The CVA6 epidemic poses a new challenge in HFMD control since there is currently no vaccine available against CVA6 infections. The Vero cell line has been widely used in vaccine production, particularly in the preparation of viral vaccines, including poliovirus vaccines and EV71 vaccines.
View Article and Find Full Text PDFNorovirus replication, host interactions and vaccine advances.
Nat Rev Microbiol
January 2025
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Human noroviruses (HuNoVs) are the leading cause of acute gastroenteritis worldwide in all age groups and cause significant disease and economic burden globally. To date, no approved vaccines or antiviral therapies are available to treat or prevent HuNoV illness. Several candidate vaccines are in clinical trials, although potential barriers to successful development must be overcome.
View Article and Find Full Text PDFNeutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.
Nat Commun
January 2025
Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate's contemporary performance. For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.
View Article and Find Full Text PDFAntibody responses in omicron BF.7-infected patients vaccinated with inactivated SARS-CoV-2.
Virology
January 2025
Xinxiang Medical College, Xinxiang, Henan, 453000, China. Electronic address:
Objective: Our study aimed to investigate antibody responses in omicron BF.7-infected patients after being vaccinated with inactivated SARS-CoV-2.
Methods: Blood serum samples were collected every 2-7 d, 1 w before infection, during the acute infection period and recovery period, and every month after recovery to detect IgG, IgM, IgA, neutralizing antibodies, and neutralizing antibodies against different omicrons in the acute phase.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!